The possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non-small cell lung cancer
Currently, lung cancer is a global problem and public health issue in the world. Chemoradiotherapy remains the optimal method in the treatment of patients with unresectable non-small cell lung cancer (NSCLC). Nowadays, immune response checkpoint inhibitors (monoclonal antibodies) are actively introd...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
QUASAR, LLC
2021-06-01
|
| Series: | Исследования и практика в медицине |
| Subjects: | |
| Online Access: | https://www.rpmj.ru/rpmj/article/view/727 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839573505616642048 |
|---|---|
| author | E. I. Smolenov G. V. Afonin V. S. Usachev D. D. Kudryavtsev I. V. Kolobaev S. A. Ivanov |
| author_facet | E. I. Smolenov G. V. Afonin V. S. Usachev D. D. Kudryavtsev I. V. Kolobaev S. A. Ivanov |
| author_sort | E. I. Smolenov |
| collection | DOAJ |
| description | Currently, lung cancer is a global problem and public health issue in the world. Chemoradiotherapy remains the optimal method in the treatment of patients with unresectable non-small cell lung cancer (NSCLC). Nowadays, immune response checkpoint inhibitors (monoclonal antibodies) are actively introduced into clinical practice which demonstrated significant improvements in the overall survival for patients with unresectable NSCLC. These drugs block programmed cell death protein (PD‑1) and programmed cell death ligand 1 (PD-L1) that increases regulation on the surface of T-cells and improves the patient's immune system respond to tumor cells. In 2019, durvalumab was introduced into clinical practice for the treatment of patients with unresectable NSCLC (stage III) after chemoradiotherapy. In our study, we’ve summarizes studies investigated the feasibility and safety of radiotherapy with immunotherapy for locally advanced lung cancer. |
| format | Article |
| id | doaj-art-3d61bb521a42428aad1601c29d0ef5db |
| institution | Matheson Library |
| issn | 2410-1893 |
| language | Russian |
| publishDate | 2021-06-01 |
| publisher | QUASAR, LLC |
| record_format | Article |
| series | Исследования и практика в медицине |
| spelling | doaj-art-3d61bb521a42428aad1601c29d0ef5db2025-08-04T14:04:04ZrusQUASAR, LLCИсследования и практика в медицине2410-18932021-06-018210912310.17709/2409-2231-2021-8-2-10382The possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non-small cell lung cancerE. I. Smolenov0G. V. Afonin1V. S. Usachev2D. D. Kudryavtsev3I. V. Kolobaev4S. A. Ivanov5A. F. Tsyb Medical Radiological Research Center – Branch of the National Medical Research Radiological CenteA. F. Tsyb Medical Radiological Research Center – Branch of the National Medical Research Radiological CenteA. F. Tsyb Medical Radiological Research Center – Branch of the National Medical Research Radiological CenteA. F. Tsyb Medical Radiological Research Center – Branch of the National Medical Research Radiological CenteA. F. Tsyb Medical Radiological Research Center – Branch of the National Medical Research Radiological CenteA. F. Tsyb Medical Radiological Research Center – Branch of the National Medical Research Radiological CenteCurrently, lung cancer is a global problem and public health issue in the world. Chemoradiotherapy remains the optimal method in the treatment of patients with unresectable non-small cell lung cancer (NSCLC). Nowadays, immune response checkpoint inhibitors (monoclonal antibodies) are actively introduced into clinical practice which demonstrated significant improvements in the overall survival for patients with unresectable NSCLC. These drugs block programmed cell death protein (PD‑1) and programmed cell death ligand 1 (PD-L1) that increases regulation on the surface of T-cells and improves the patient's immune system respond to tumor cells. In 2019, durvalumab was introduced into clinical practice for the treatment of patients with unresectable NSCLC (stage III) after chemoradiotherapy. In our study, we’ve summarizes studies investigated the feasibility and safety of radiotherapy with immunotherapy for locally advanced lung cancer.https://www.rpmj.ru/rpmj/article/view/727non-small cell lung cancernsclcradiotherapychemotherapyimmunotherapymonoclonal antibodypd inhibitorchemoradiotherapy |
| spellingShingle | E. I. Smolenov G. V. Afonin V. S. Usachev D. D. Kudryavtsev I. V. Kolobaev S. A. Ivanov The possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non-small cell lung cancer Исследования и практика в медицине non-small cell lung cancer nsclc radiotherapy chemotherapy immunotherapy monoclonal antibody pd inhibitor chemoradiotherapy |
| title | The possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non-small cell lung cancer |
| title_full | The possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non-small cell lung cancer |
| title_fullStr | The possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non-small cell lung cancer |
| title_full_unstemmed | The possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non-small cell lung cancer |
| title_short | The possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non-small cell lung cancer |
| title_sort | possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non small cell lung cancer |
| topic | non-small cell lung cancer nsclc radiotherapy chemotherapy immunotherapy monoclonal antibody pd inhibitor chemoradiotherapy |
| url | https://www.rpmj.ru/rpmj/article/view/727 |
| work_keys_str_mv | AT eismolenov thepossibilitiesofcombinationimmunotherapywithradiationtherapyforthetreatmentofpatientswithinoperablelocallyadvancednonsmallcelllungcancer AT gvafonin thepossibilitiesofcombinationimmunotherapywithradiationtherapyforthetreatmentofpatientswithinoperablelocallyadvancednonsmallcelllungcancer AT vsusachev thepossibilitiesofcombinationimmunotherapywithradiationtherapyforthetreatmentofpatientswithinoperablelocallyadvancednonsmallcelllungcancer AT ddkudryavtsev thepossibilitiesofcombinationimmunotherapywithradiationtherapyforthetreatmentofpatientswithinoperablelocallyadvancednonsmallcelllungcancer AT ivkolobaev thepossibilitiesofcombinationimmunotherapywithradiationtherapyforthetreatmentofpatientswithinoperablelocallyadvancednonsmallcelllungcancer AT saivanov thepossibilitiesofcombinationimmunotherapywithradiationtherapyforthetreatmentofpatientswithinoperablelocallyadvancednonsmallcelllungcancer AT eismolenov possibilitiesofcombinationimmunotherapywithradiationtherapyforthetreatmentofpatientswithinoperablelocallyadvancednonsmallcelllungcancer AT gvafonin possibilitiesofcombinationimmunotherapywithradiationtherapyforthetreatmentofpatientswithinoperablelocallyadvancednonsmallcelllungcancer AT vsusachev possibilitiesofcombinationimmunotherapywithradiationtherapyforthetreatmentofpatientswithinoperablelocallyadvancednonsmallcelllungcancer AT ddkudryavtsev possibilitiesofcombinationimmunotherapywithradiationtherapyforthetreatmentofpatientswithinoperablelocallyadvancednonsmallcelllungcancer AT ivkolobaev possibilitiesofcombinationimmunotherapywithradiationtherapyforthetreatmentofpatientswithinoperablelocallyadvancednonsmallcelllungcancer AT saivanov possibilitiesofcombinationimmunotherapywithradiationtherapyforthetreatmentofpatientswithinoperablelocallyadvancednonsmallcelllungcancer |